Pfizer Stock-Based Compensation 2010-2025 | PFE
Pfizer annual/quarterly stock-based compensation history and growth rate from 2010 to 2025. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors
- Pfizer stock-based compensation for the quarter ending March 31, 2025 was $170M, a 22.73% decline year-over-year.
- Pfizer stock-based compensation for the twelve months ending March 31, 2025 was $2.173B, a 54.99% increase year-over-year.
- Pfizer annual stock-based compensation for 2024 was $0.877B, a 67.05% increase from 2023.
- Pfizer annual stock-based compensation for 2023 was $0.525B, a 39.79% decline from 2022.
- Pfizer annual stock-based compensation for 2022 was $0.872B, a 26.23% decline from 2021.
Pfizer Annual Stock-Based Compensation
(Millions of US $) |
| 2024 |
$877 |
| 2023 |
$525 |
| 2022 |
$872 |
| 2021 |
$1,182 |
| 2020 |
$755 |
| 2019 |
$687 |
| 2018 |
$923 |
| 2017 |
$840 |
| 2016 |
$691 |
| 2015 |
$669 |
| 2014 |
$586 |
| 2013 |
$523 |
| 2012 |
$481 |
| 2011 |
$419 |
| 2010 |
$405 |
| 2009 |
$349 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$139.751B |
$63.627B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
